Stifel analyst, Adam Walsh, reiterated a Buy rating and $90.00 price target on Ultragenyx Pharma (NASDAQ: RARE) following the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE